Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivumecirnon - RAPT Therapeutics

Drug Profile

Tivumecirnon - RAPT Therapeutics

Alternative Names: FLX-475

Latest Information Update: 08 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FLX Bio
  • Developer Hanmi Pharmaceutical; Merck & Co; RAPT Therapeutics
  • Class 2 ring heterocyclic compounds; Antineoplastics; Azetidines; Piperidines; Pyrazines; Pyrazoles; Small molecules
  • Mechanism of Action CCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer; Gastric cancer; Malignant melanoma

Most Recent Events

  • 03 Nov 2023 Updated safety and efficacy data from the phase I/II trial in Advanced Non-small cell lung cancer released by RAPT Therapeutics
  • 17 Oct 2023 Hanmi Pharmaceutical and Merck complete a phase II trial for Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (PO, Tablet) (NCT04768686)
  • 20 Sep 2023 Pharmacodynamics and efficacy data from a phase-I/II trial in Cancer presented at the Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top